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Abstract
Background: The management of articular cartilage defects presents many clinical challenges due to its avascular,
aneural and alymphatic nature. Bone marrow stimulation techniques, such as microfracture, are the most frequently
used method in clinical practice however the resulting mixed fibrocartilage tissue which is inferior to native hyaline
cartilage. Other methods have shown promise but are far from perfect. There is an unmet need and growing
interest in regenerative medicine and tissue engineering to improve the outcome for patients requiring cartilage
repair. Many published reviews on cartilage repair only list human clinical trials, underestimating the wealth of basic
sciences and animal studies that are precursors to future research. We therefore set out to perform a systematic
review of the literature to assess the translation of stem cell therapy to explore what research had been carried out
at each of the stages of translation from bench-top (in vitro), animal (pre-clinical) and human studies (clinical) and
assemble an evidence-based cascade for the responsible introduction of stem cell therapy for cartilage defects.
Main body of abstract: This review was conducted in accordance to PRISMA guidelines using CINHAL, MEDLINE,
EMBASE, Scopus and Web of Knowledge databases from 1st January 1900 to 30th June 2015. In total, there were
2880 studies identified of which 252 studies were included for analysis (100 articles for in vitro studies, 111 studies
for animal studies; and 31 studies for human studies). There was a huge variance in cell source in pre-clinical
studies both of terms of animal used, location of harvest (fat, marrow, blood or synovium) and allogeneicity. The
use of scaffolds, growth factors, number of cell passages and number of cells used was hugely heterogeneous.
Short conclusions: This review offers a comprehensive assessment of the evidence behind the translation of
basic science to the clinical practice of cartilage repair. It has revealed a lack of connectivity between the in vitro,
pre-clinical and human data and a patchwork quilt of synergistic evidence. Drivers for progress in this space are
largely driven by patient demand, surgeon inquisition and a regulatory framework that is learning at the same pace
as new developments take place.
Keywords: Matrix-induced autologous chondrocyte implantation, Autologous chondrocyte implantation,
Mesenchymal stem cells
Background
Articular cartilage is a highly specialised tissue acting as
a shock absorber, enabling synovial joints to articulate
with low frictional forces. Due to its avascular, aneural
and alymphatic state, it has a limited repair potential [1].
Surgical options to manage damaged articular cartilage
include arthroscopic debridement [2–5], bone marrow
stimulation techniques [6–8], chondrocyte implantation
[9–13], osteochondral autografts (mosaicplasty) [2, 14, 15],
osteochondral allograft [16–18] and, in the presence of
osteoarthritis, joint replacement [19].
Bone marrow stimulation techniques, such as micro-
fracture, are the most frequently used method in clinical
practice for treating small symptomatic lesions of the
articular cartilage [6–8]. However, the resulting tissue
has shown to be a mixed fibrocartilage tissue [20–22]
with varying amounts of type II collagen [8, 21, 23, 24]
and inferior to native hyaline cartilage. Fibrocartilage is
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vulnerable to shear stresses and prone to breaking down
over time [20]. Subchondral osseous overgrowth has also
been reported after microfracture [25, 26]. Osteochon-
dral grafts can lead to donor site morbidity and healing
seams at the recipient site [27, 28]. Autologous chondro-
cyte implantation (ACI) [9, 10] and its later evolution,
matrix-induced autologous chondrocyte implantation
(MACI), offered great promise with 80% of patients
showing good or excellent results at 10 years [29] but at
best results in hyaline-like repair and has experienced
complications such as graft failure, periosteal hyper-
trophy and delamination [30, 31]. In addition, it has also
been reported that cells may lose their phenotype during
expansion [32, 33].
There is therefore a growing interest in regenerative
medicine, which can broadly be thought of as two main
types: cell therapy, where cells are injected directly into
the blood or into tissues, and tissue engineering, where
cell-scaffold combinations are used to repair or regener-
ate tissues.
Stem cells are cells that have the ability to divide and
develop into many different cell types in the body and
can be categorised as pluripotent and multipotent. Pluri-
potent stem cells are often harvested from embryonic
sources and can develop into any type of cell in the body
whereas multipotent stem cells are generally taken from
adults and can divide and develop into a more limited
range of cell types. When stem cells divide, the new cells
can either remain stem cells or develop into a new type
of cell with a more specific function (Table 1).
Mesenchymal stem cells (MSCs) are a form of
multipotent cells that may offer an alternative to cartil-
age repair techniques not hampered by availability and
donor site morbidity.
The introduction of stem cell therapies into clinical
practice however is a form of translational research,
which as per any “bench-to-bedside” pathway now has
enormous governance issues [34, 35] and is highly regu-
latory across four phases (Table 2) and by the Tissues
and Cells Directive (2004/23/EC) https://www.hta.
gov.uk/policies/eu-tissue-and-cells-directives.
Many published reviews on cartilage repair only list
human clinical trials [13, 36–46], underestimating the
wealth of basic sciences and animal studies that are pre-
cursors to future research and may be relevant in clinical
practice further down the line. In addition, true transla-
tion would imply that all of the clinical studies would
have supporting pre-clinical data.
We therefore set out to perform a systematic review of
the literature to assess the translation of stem cell
therapy to explore what research had been carried out at
each of the stages of translation from bench-top (in
vitro), animal (pre-clinical), and human studies (clinical)
and assemble an evidence-based cascade for the respon-
sible introduction of stem cell therapy for cartilage
defects. In particular, we wanted to focus on the key
burning questions pertaining to cartilage repair such as
cell source, dosage (how many cells should be used),




This review was conducted in accordance to PRISMA
guidelines [47] using CINHAL, MEDLINE, EMBASE,
Scopus and Web of Knowledge databases from 1st
January 1900 to 30th June 2015.
The keywords used in the selection were “(“mesenchy-
mal stem cells”[All Fields] OR “mesenchymal stem
cells”[MeSH Terms] OR “mesenchymal”[All Fields] OR
“stem cells”[All Fields] OR “Stem Cells”[MeSH Terms]
OR “MSC”[All Fields]) AND (“Articular Cartilage”[MeSH
Terms] OR “articular”[All Fields] OR “cartilage”[All
Fields] OR “cartilage”[MeSH Terms]) AND (“healing”[All
Terms] OR “repair”[All Terms] OR “Regeneration”[MeSH
Terms] OR “regeneration”[All Fields] OR “tissue engi-
neering”[MeSH Terms] OR “tissue engineering”[All
Fields]) AND (“defect”[All Terms]) AND (“chond*”[All
Terms])”.
All review and non-English studies were excluded. For
analysis, only original research studies were included.
Any duplicates were excluded. Initially, KM and JS inde-
pendently screened studies’ title and abstract. Those
Table 1 Table describing the three main properties of stem cells
Stem cell properties
• They are unspecialized (“blank slates” that can become specific
types of cells).
• They can develop into specialized cell types (cells that do specific
work in the body).
• They are capable of surviving over long periods and divide to make
additional stem cells.
Table 2 Description of the different phases of clinical trials
Clinical trial phases (http://www.nlm.nih.gov/services/ctphases.html)
Phase I: Safety Studies or First-In-Man. Researchers test a new drug or
treatment in a small group of people for the first time to evaluate its
safety, determine a safe dosage range, and identify side effects.
Phase II: Uncontrolled Efficacy Studies. The drug or treatment is given
to a larger group of people to see if it is effective and to further
evaluate its safety.
Phase III: Randomised Clinical Trials. The drug or treatment is given to
large groups of people to confirm its effectiveness, monitor side
effects, compare it to commonly used treatments, and collect
information that will allow the drug or treatment to be used safely.
Phase IV: Post-Market Surveillance. Studies are done after the drug or
treatment has been marketed to gather information on the drug’s
effect in various populations and any side effects associated with
long-term use.
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included had the full text reviewed. Any disparities were
discussed with the senior author (AJG). The references
of eligible studies were also searched and included where
relevant.
Unpublished trial databases (e.g. ClinicalTrials.gov)
were reviewed as the grey literature using popular search
engines, including Google. The keywords used for
registered clinical trials in clinical trial databases were
“stem cells”, “cartilage” and “orthopaedics”.
Eligible studies were drafted into tables tabulating the
key data.
Results
The initial search identified 2880 study articles, of which
239 were included for analysis. The PRISMA flow
diagram is shown in Fig. 1.
In vitro studies
MSC source A list of cell sources used in the in vitro
studies is shown in Table 3. The commonest being
human MSCs (66%) followed by rabbit MSCs (15%). The
majority of the studies used bone marrow-derived MSCs
(63%) followed by adipose tissue (33%). Two studies
used commercial cell lines [48, 49].
Scaffold Within the in vitro studies, 26 different types
of natural scaffold and 9 types of synthetic scaffolds were
identified with a further 18 different types of hybrids,
the most popular being a fibrin-polyurethane scaffold
(Table 4).
Growth factors The commonest used growth factors
were TGF-β and the bone morphogenetic protein (BMP)
family. A list of growth factors used can be seen in
Table 5.
Cell seeding and passage There was wide heterogeneity
in cell seeding density and there appeared to be no
standard form of measurement. Li et al. [50] examined
three different seeding densities: 2, 5 and 10 × 106 cells/
scaffold, and found that scaffolds seeded with 5 × 106
cells per scaffold induced the highest chondrogenesis;
however, other groups [51–53] found that a higher
seeding density results in better chondrogenesis.
Apart from 26 studies which did not state cell passage
number, most studies used MSC of an early passage,
anything between uncultured fresh (passage zero (P0)
and five times passaged cells (P5). One study used cells
of P6 [54], and another study used cells between P4 and
P7 [48]. No relationship was apparent between chondro-
genesis and number of passages.
Length of study The length of each in vitro study can
be seen in Table 6. The majority of studies were short-
term models; 27 studies (25%) ended between 1 and
2 weeks, 35 studies (33%) ended between 2 and 3 weeks
and 15 studies (14%) ended between 3 and 4 weeks.
Method of assessment A range of techniques was used
to assess chondrogenesis within the in vitro studies.
These techniques consisted of histology, immunohisto-
chemistry, qPCR, biochemical analysis, imagery and
mechanical testing. The techniques used are summarised
in Table 7.
Animal studies (pre-clinical)
One hundred eleven animal studies were included of
which 109 were controlled laboratory studies, one was a
Fig. 1 Flow chart of literature search used for the review
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pilot study [49] and one was a longitudinal case study
on a race horse [55]. The commonest animal studied
with 59 studies was rabbit (53%). The different species
of animals studied is shown in Table 8.
Defect The size of the defect varied from 2 to 25 mm2
in the smaller animals and from 1 to 64 mm2 in the
larger animals. All but two studies [56, 57] used the knee
for defect creation.
Stem cell type Bone marrow-derived stem cells were
used in 84 studies (75%). Thirteen studies (11%) used
adipose stem cells [54, 58–69], six (5%) used synovia
[70–75] and three (2%) used periostium-derived MSCs
[76–78]. Three studies (3%) used embryonic stem cell-
derived MSCs [79–81] whereas 2 studies (2%) used
muscle-derived MSCs [82, 83]. One group showed
promising results of allogenic MSCs in a rabbit model
when compared to autologous cells, although numbers
were small [84, 85]. Another used compared autologous
chondroprogenitor cells and allogenic chondroprogeni-
tor cells against controls in an equine model and
reported that repair tissue quality in the allogenic cell
group was not superior to that in the control (fibrin
only) group and also showed poorer radiographic
changes in the allogenic group [23].
Cell culture, dose and delivery There was much vari-
ation in the number of cells implanted and the number
of cell passages from 3–10 or more [79, 86].
The number of cells varied from 4 × 103 – 1 × 1010.
The majority of studies used between 106 and 108
cells. Some did not specify the number of cells
implanted. Two studies suggested that improved
chondrogenesis occurs with a higher implanted cell
number [75, 87], although others suggested that the high
cell numbers increase the risk of synovitis [75] and
synovial proliferation [88].
The cells were transplanted into the defect both as
cell therapy (injection directly into the joint) (17
studies, 15%) or by tissue engineering (cell-scaffold
combinations) (94 studies, 85%). Fifteen studies [49, 65,
72, 75, 81, 86, 89–97] used a mixture of solutions pre-
pared from hyaluronic acid [65, 92, 94–97], phosphate
buffer solution [91], plasma [75], basal medium with
chondrogenesis [89], collagen acid [93], sodium alginate
[86] or a growth factor medium [90]. Two studies used
MSCs only [49, 72].
Scaffold Ninety-two studies (82%) used a scaffold. The
material used was a synthetic polymer either collagen
based, fibrinogen glue or a synthetic protein (e.g.
rHuBMP-2) in 62 (56%) studies (Table 9).
Growth factors Thirty-two studies (29%) assessed the
effect of growth factors on MSC chondrogenesis. Seven-
teen out of 38 (44%) used TGF-β1/3 (Table 10), the ma-
jority of which show a positive effect on chondrogenesis.
Associated procedures Ten of the studies compared
MSC treatment against other surgical modalities such as
debridement [55], microfracture [49, 91, 96, 98, 99] and
mosaicplasty [77, 100–102].
Outcome measures There were a variety of outcome
measures used to analyse the results of the studies. The
majority of studies (79%) used evidence of hyaline-like
cartilage as being a positive outcome (Tables 11 and 12).
Table 3 Cell species and cell sources
Cell species No. of
studies
References Cell Source No. of
studiesa
References
Human 73 [48, 50, 52, 53, 168–236] Bone marrow 62 [48, 50–53, 164, 168, 170–173, 177–180, 182–185,
187, 188, 192, 195–197, 203, 206–210, 212, 216,
217, 219, 221, 223, 227, 230, 232–235, 237–255]
Rabbit 17 [240–242, 246, 249, 252, 255–265] Adipose 36 [66, 169, 175, 176, 181, 186, 189, 193, 194, 199,
201, 202, 211, 214, 216, 218–220, 224, 228, 229,
231, 235, 242, 256, 257, 260–269]
Bovine 5 [51, 164, 243, 245, 270] Synovium 9 [174, 191, 200, 213, 222, 226, 258, 259, 270]
Rat/mouse 5 [239, 250, 266, 269, 271] Umbilical cord blood 3 [205, 236, 190]
Porcine 3 [247, 248, 268] Commercial cell line 2 [215, 271]
Equine 3 [238, 253, 254] Placental 2 [198, 225]
Goat 1 [244] Embryonic 1 [216]
Ovine 2 [237, 251] Not stated 0
Not stated 1 [267]
aSome studies used cells from more than one cell source
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Human studies (clinical)
Thirty-one published studies by 15 different groups
looked at clinical applications of MSCs. One used allo-
genic stem cells [103] and the rest autologous stem cells.
The types of studies can be seen in Tables 13 and 14.
There were 52 unpublished clinical trials, majority of
which are early phase studies (I–II; 63%) and only 5
trials were phase II/III. Table 15 shows a summary of
these clinical trials.
Defects The majority of studies (42%) used MSCs to
treat knee osteoarthritis [103–115]. The rest of the
studies looked at knee cartilage defects except for two
which studied the ankle talar dome [116, 117]. One
study used MSCs to treat knee osteoarthritis (OA), knee
OA and ankle OA [112].
Of the knee cartilage defects, the patients were
heterogeneous with varying defect sizes and locations,
including the patellae [118–121], patella-femoral joints
[122, 123], femoral condyle [113, 119–121, 123–132],
trochlear [119–121] and tibial plateau [121]; and several
had multiple defect sites [105, 120, 123, 128].
Previous treatment and associated procedures The
majority of patients who received MSC treatment had
undergone previous arthroscopy [103, 104, 118, 119,
122, 124, 130], failed debridement [113, 118, 119,
Table 4 Types of scaffolds
Number of studies using types of scaffold








Types of scaffolds used
Natural scaffolds
Type I collagen hydrogel 6 [185, 190, 211, 226,
241, 251]
Agarose hydrogel 4 [53, 247, 248, 268]
Alginate bead 3 [223, 231, 271]
Fibrin hydrogel 3 [208, 211, 263]
Silk fibroin 3 [198, 216, 256]
Chitosan microspheres 2 [260, 262]
Hyaluronic acid 2 [195, 237]
Cartilage-derived matrix 2 [193, 238]
K-carrageenan 2 [169, 199]
Chitosan 2 [168, 216]
Hyaluronic acid hydrogel 2 [164, 245]
Gelatin-based scaffold 2 [176, 233]
Devitalised cartilage ECM 1 [220]
Bead in bead alginate polysaccharide capsules 1 [221]
Atelocollagen gel 1 [225]
Fibrin disk 1 [254]
Methacrylated hyaluronic acid 1 [164]
Gelatin microspheres 1 [260]
Decellularised cell matrix 1 [191]
Collagen type I microspheres 1 [52]
Alginate microbeads 1 [266]
Alginate disks 1 [270]
Platelet rich plasma 1 [242]
Free oligosaccharide chondroitin sulphate C 1 [205]
Collagen type I sponge 1 [237]
3D printed chitosan 1 [181]
Synthetic scaffolds
Polycaprolactone 3 [197, 207, 209]
PLGA 3 [194, 204, 257]





GFOGER modified PEG hydrogel 1 [183]
OPF hydrogel 1 [240]
Hybrid scaffolds
Fibrin–polurethane hydrogel 4 [50, 188, 192, 267]
Esterified hyaluronan and gelatin polymer 2 [212, 255]
TruFit CB (PLGA, calcium sulphate and
polycolide)
1 [187]
Table 4 Types of scaffolds (Continued)
PCL–HA bilayer 1 [243]
PEGDG–crosslinked hyaluronic acid 1 [202]
Polylactic acid–alginate 1 [232]
Sodium alginate–hyaluronic acid 1 [189]
Chitosan–collagen type I 1 [258]
Polyvinylalcohol–polycaprolactone 1 [246]
Tricalcium phosphate-collagen-hyaluronan 1 [180]
Poly-L-lactic acid–hydroxyapatite 1 [215]
Collagen type I–polylactic acid 1 [217]
Polylactic acid–polyglycolic acid with fibrin 1 [261]
Collagen–polyglycolic acid 1 [252]
Chondroitin sulphate C–collagen type II 1 [236]
Fibrin hydrogel with chondroitin sulphate 1 [263]
Chitosan-demineralised bone matrix 1 [239]
Alginate foam-chondroitin sulphate 1 [170]
Growth factor combined with scaffolds
TGF-β1-loaded microspheres with chitosan
microspheres
1 [262]
TGF-β1 releasing chitosan-collagen hydrogel 1 [174]
PEOT/PBT TGF-β1 loaded scaffolds 1 [173]
TGF-β1-activated chitosan/gelatin 1 [249]
PLGA nanospheres with TGF-β1 1 [172]
TGF-β1 loaded Gelatin Microspheres 1 [175]
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121–123, 125, 127, 131] or bone marrow stimulation
[114, 116, 117, 126].
Cell harvest source Twenty-one studies (68%) used
bone marrow-derived MSCs from the anterior or pos-
terior superior iliac spine [103–105, 109, 111–113,
115–118, 120, 122–128, 130–132]. Five studies (18%)
used adipose-derived MSCs [106–108, 110, 114], two
studies (7%) used synovium-derived MSCs [129, 133]
and two studies (7%) used peripheral blood progenitor
cells collected by apheresis [119, 121].
Cell stage Twenty studies (61%) culture-expanded
their cells [103–105, 107–113, 115, 118, 120, 122–
126, 129, 133], whereas 11 studies (39%) used fresh
concentrated stem cells from bone marrow [116, 117,
127, 128, 130–132], fat tissues [106, 114] or periph-
eral blood [119, 121] in a one stage-procedure. In
studies using bone marrow concentrate, approximately
60 ml of bone marrow aspirate was harvested and
concentrated down to a volume of 2–4 ml before use
[116, 117, 127, 130–132]. In studies using culture-
expanded cells, the majority used cells from early
passages, P1–P3 [103, 105, 109, 110, 112, 113, 115,
118, 120, 122–125, 129]. One study reported the use
of cells at a late passage (P5) [104] ,and five studies
did not specify a passage number [107, 108, 111,
126, 133].
Thirteen studies (42%) confirmed the phenotype of
cells before clinical application [105, 108–110, 112, 115,
119, 120, 122–125, 129]. Commonly used surface
markers to select MSCs were CD29, CD44, CD73, CD90
and CD105. Also CD14, CD34 and HLA-DR were used
to eliminate non-MSCs.
Cell dose and delivery The number of cells applied
(dose) varied from 2–57 million for bone marrow-derived
Table 5 Number of in vitro studies using different growth factors
Growth factor No. of
studies (%)
References Growth factor No. of
studies (%)
References
TGF-β1 48 (44%) [50, 169–175, 189, 190, 192, 193, 195, 199, 202,
208, 210, 211, 213, 214, 216, 217, 220, 222–224,
228, 230–232, 234, 235, 244, 246, 249, 252–256,
258, 260–263, 266, 267, 270]
SOX-5 1 (1%) [204]
TGF-β3 32 (29%) [51, 162, 164, 168, 177, 181–184, 197, 200, 205–207,
218, 223–225, 227, 237, 239, 240, 245, 247, 248,
250, 251, 257, 259, 267, 268, 270]
SOX-6 1 (1%) [204]
BMP-2 13 (12%) [188, 202, 213, 219, 225–227, 229, 264, 265,
267, 270, 271]
WNT3A 1 (1%) [171]
FGF 9 (8%) [171, 183, 193, 197, 198, 213, 225, 246, 258] IL-1 1 (1%) [197]
IGF-1 7 (6%) [179, 184, 192, 213, 224, 254, 265] EGF 1(1%) [193]
BMP-6 7 (6%) [181, 216, 219, 224, 227, 250, 266] OP-1 1 (1%) [222]
TGF-β2 4 (4%) [209, 219, 238, 270] AA2P 1 (1%) [266]
GDF-5 3 (3%[ [48, 186, 269] IL-10 1 (1%) [178]
SOX-9 2 (2%) [204, 221] TNFα 1 (1%) [178]
BMP-4 2 (2%) [227, 271] PRP 1 (1%) [242]
DEX 2 (2%) [224, 266] IWP2 1 (1%) [171]
BMP-7 1 (1%) [219] None 15 (14%) [52, 176, 180, 185, 187, 191, 194, 196,
201, 212, 215, 233, 236, 241, 243]
PDGF 1 (1%) [202]
Table 6 Length of studies
Length of study No. of
studies
References
Up to 1 week 9 [172, 203, 210, 212, 224, 229, 239, 266, 270]
1–2 weeks 27 [50, 170, 174, 178, 182, 189, 192, 194, 198,
202, 215, 218, 220, 223, 228, 234, 235, 237,
240, 249, 254, 260–265]
2–3 weeks 36 [52, 53, 168, 169, 173, 175, 179, 180, 183–186,
190, 191, 195, 196, 199, 200, 204, 205, 209, 213,
217, 225, 226, 230, 232, 233, 236, 246, 250, 256,
258, 269, 271]
3–4 weeks 15 [51, 176, 181, 188, 193, 201, 211, 216, 219,
221, 241, 251, 253, 255, 257]
4–5 weeks 7 [171, 177, 206, 214, 231, 259, 267]
5–6 weeks 10 [48, 187, 208, 222, 238, 244, 247, 248, 252, 268]
6–7 weeks 1 [207]
7–8 weeks 1 [197]
8–9 weeks 3 [164, 243, 245]
Not stated 1 [242]
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MSCs [103–105, 109, 111–113, 118, 120, 122–125, 129]
and from 1.2–100 million for adipose-derived MSCs
[107, 108, 110, 114]. For synovial MSCs, 8–77 million
cells were used [129, 133], and for peripheral blood
progenitor cells, 20 million cells were used [119].
Also, the methods for implantation varied from
arthroscopic implantation (35%) [107, 108, 116, 117,
127, 128, 130–133], intra-articular injection [103–106,
109–112, 114, 115, 119, 121, 123] or open surgery
(29%) [113, 118, 120, 122–126, 129].
In the cell therapy studies, the cells were sus-
pended with a variety of different co-stimulators,
including hydroxyapatite (HA) [106, 119, 121, 123],
platelet rich plasma (PRP) [106, 114] and platelet
lysate [104]. Some studies also administered multiple
injections of stem cells [119, 121] and/or further
injection of HA [115, 119, 121, 123], PRP [106,
114] or nucleated cells [104] following a stem cell
injection.
The most frequently used scaffolds were type I
collagen of porcine or bovine origin [113, 118, 122,
124, 126, 129], followed by ascorbic acid sheet [120,
123] and platelet-rich fibrin glue mixture [108, 125].
Rehabilitation Early continuous passive motion was
employed in 14 studies [113, 117–122, 124–127, 129–
131]. Six studies did not report details on post-
operation rehabilitation [104–106, 109, 116, 132].
Three studies aimed for full weight bearing very early
by week 4 [107, 108, 122] whereas 11 studies (40%)
aimed for full weight bearing by the 6th–8th week
[113, 117–121, 124, 125, 127, 131, 133]. No study
addressed the effect of rehabilitation on the quality of
the repair.
Outcomes Most commonly used outcome measures for
treatment efficacy were radiological (77%) [103–106,
109–112, 115–117, 119, 121, 123–125, 127–134] and
arthroscopic assessment (61%) [107, 108, 113, 116–122,
124–126, 130–133]. Most commonly used patient-
reported outcomes are International Knee Documenta-
tion Committee (IKDC) score (36%), followed by a visual
analogue scale (VAS) pain (39%) and Tegner activity
scale (29%).
Adverse effects None of the studies reported any severe
adverse effects related to the MSC treatment. Two
group reported minor adverse events including mild
pain and effusion after the injections, which persisted
for no more than 7 days [103, 114].
Conclusions
There is a growing fascination with the role of mesen-
chymal stem cells in cartilage repair.
As early as the 1950s, Pridie showed fibrocartilagi-
nous repair through subchondral drilling [135–137].
Initially, Pridie drilling was reported as a treatment
for osteoarthritis [135, 138] and was often associated
Table 7 Types of techniques used to assess chondrogenesis of MSCs
Type of techniques No. of studies (%) References
Histology 87 (79%) [48, 50–53, 164, 168–170, 173–175, 177–179, 181–187, 191–195, 197–201, 204–211, 213–217, 219–222, 226,
229, 230, 232–238, 240–248, 250, 252–264, 267–271]
Immunohistochemistry 78 (71%) [48, 50, 52, 53, 168–171, 173–175, 178–183, 185–191, 193, 194, 197, 198, 201, 203–205, 207, 212–215,
217, 218, 220, 221, 224, 226, 228–238, 241, 242, 244, 246–248, 250–259, 264, 265, 267–271]
qPCR 70 (64%) [53, 168, 169, 173, 174, 176, 178–186, 188, 190, 192–194, 196, 199, 200, 202–205, 207–209, 211, 214, 216–220,
222–232, 235, 236, 239, 240, 242, 246, 249–251, 256, 258, 259, 261–263, 265–267, 269–271]
Biochemical analysis 64 (58%) [48, 50–52, 164, 168, 170–172, 176, 177, 179, 180, 182–184, 188, 189, 191, 192, 197, 199, 200, 202, 204, 205,
209, 212, 214, 216–219, 222–224, 226, 227, 233–240, 244, 245, 247–249, 252, 254, 257, 260–266, 268–270]
Imaging (confocal, SEM, TEM) 24 (22%) [52, 172, 176, 180, 185, 187, 194, 198, 208, 215–217, 225, 226, 230, 232, 241, 242, 249, 252, 255, 262, 263, 265]
Mechanical testing 15 (14%) [51, 52, 164, 169, 175, 193, 197, 207, 220, 245, 247, 248, 256, 257, 268]
Table 8 Different species of animals used to assess reparative




Rabbits 57 (51%) [49, 54–102, 134, 150–154, 160, 161, 207, 272–324]
Pigs 16 (14%) [61, 62, 68–72, 87, 90, 153, 273, 276, 279, 290,
308–310]
Rats 13 (12%) [60, 78–82, 91, 152, 160, 278, 286, 311, 312]
Sheep 8 (7%) [89, 272, 282, 283, 313–316]
Goats 5 (5%) [49, 95, 100, 101, 318]
Horses 4 (4%) [55, 96, 98, 317]
Dogs 4 (4%) [86, 97, 151, 287]




Donkeys 1 (<1%) [57]
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with many additional procedures such as synovectomy
and trimming of osteophytes.
Since Pridie’s initial experiments, the process of mar-
row stimulation techniques or exposure of mesenchymal
Table 9 Table showing the types of scaffold used in animal
studies
Scaffold type No. of
studies
References
No Scaffold 19 (17%) [49, 54, 61, 70, 72–75, 81,
86, 89–91, 97, 100, 102,
280–282, 284]
Poly (lactide-co-glycoside) PLGA 17 (16%) [56, 59, 62, 63, 83, 88, 150,
153, 160, 277, 285, 286,
289–292, 316]
Fibrin/Fribrin glue 11 (9%) [55, 64, 76–78, 152, 278,
293, 308, 317, 318]
Hydrogel 9 (8%) [65, 69, 81, 94, 279, 288, 314,
321, 323]
Collagen 9 (8%) [79, 80, 134, 276, 299, 301,
309, 320, 322]
Hyaluronic acid 7 (6%) [57, 92, 95, 96, 273, 304,
324]
Alginate beads 4 (3%) [65, 84, 101, 294]
Tissue membrane 4 (3%) [82, 98, 303, 305]
Polyglycolic acid 3 (3%) [99, 161, 274]
PGA/PLA 3 (3%) [68, 290, 296]
Hylauronan crosslinked matrix 2 (2%) [154, 297]
Poly-L-lactide-co-caprolactone 2 (2%) [275, 300]
Polycaprolactone cartilage (PCL) 2 (2%) [87, 272]
Animal-origin osteochondral plug scaffold 2 (2%) [272, 298]
Chitosan microspheres and fibrin glue 1 (<1%) [60]
Gel carries (collagen/HA/Fibrogen) 1 (<1%) [71]
Polychoxanone/poly(vinyl alcholo) PDO/PVA 1 (<1%) [302]








MSC-ADM (accellulo-dermal matrix) 1 (<1%) [319]
Hyaff-11 scaffold 1 (<1%) [295]
Porous-gelatin-chonroitin hyaluronate 1 (<1%) [291]
Bone protein 7 PCL 1 (<1%) [66]
Human acellular amniotic membrane 1 (<1%) [307]
Pluronic-F 127 1 (<1%) [102]
Tricalcium phosphate 1 (<1%) [315]
Agarose 1 (<1%) [311]




Magnet 1 (<1%) [310]
Human cartilage extra cellular matrix 3D
porous acellular
1 (<1%) [67]
Table 10 Table showing growth factors used in animal studies





[56, 65, 66, 70, 76, 85, 90, 100,
280, 282, 285, 287, 290, 291, 309,
311, 323]
CDMP–1 2 (2%) [56, 134]
FGF-2 2 (2%) [90, 304]
Ad-hTGF-B1 1 (<1%) [321]
AdBMP–2 1 (<1%) [78]
chABC 1 (<1%) [74]
PRP 1 (<1%) [75]
Gene modified MSCs (gene
modification to BcL-xL gene)
1 (<1%) [299]
hiGF-1-DNA 1 (<1%) [101]
AdIGF–1 1 (<1%) [78]
rHuBMP–2 1 (<1%) [82]
Ham-F-12 1 (<1%) [303]
NaO11 1 (<1%) [277]
NSC23766-Rac1 inhibitor 1 (<1%) [60]
Table 11 Outcome measures used in animal studies (some
studies used more than one outcome measure)








26 (23%) [49, 60, 61, 63, 66, 69, 72, 74, 79, 89, 92,
94, 98, 99, 272, 282, 283, 289, 305, 306,
310, 313, 314, 316, 319, 324]
Wakitani score 21 (19%) [58, 62, 67, 68, 72, 73, 80, 82, 97, 151,
273, 277, 279, 284, 285, 290, 299, 304,
310, 321]
O’Driscoll score 2018% [49, 71, 81, 84, 85, 93, 100, 160, 272, 276,
290, 296–298, 302, 306, 308, 313, 314, 322]
Functional scores/
mechanical
11 (10%) [55, 57, 62, 67, 69, 81, 101, 277, 287,
290, 315]
MRI scores 5 (5%) [63, 69, 96, 101, 316]
Arthroscopy scores 5 (5%) [72, 96, 310, 317, 318]
Macroscopic osteoarthritis
score
3 (3%) [57, 281, 295]
Pineda score 3 (3%) [290, 293, 309]
Schreiber score 2 (2%) [101, 300]
Britternberg score 2 (2%) [84, 85]
Slochagg score 1 (<1%) [300]
Moran score 1 (<1%) [64]
Gill score 1 (<1%) [95]
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stem cells from cancellous bone has changed its guise
on several occasions.
Ficat in 1979 described “Spongialization” in which
the cancellous bed was exposed in 85 patients with
chondral lesions of the patella with encouraging re-
sults [139]. Johnson et al. [140] described abrasion
arthroplasty and encouraged its use especially in
younger patients [141, 142]. Other authors had less
positive outcomes [143–146]. Dandy wrote an enter-
taining article on abrasion arthroplasty where he
highlighted that at least in the treatment of osteo-
arthritis, its effects could relate to the arthroscopic
washout, rest or even the placebo effects of the cha-
rismatic surgeon [147]. The final evolution of marrow
stimulation was the term “Microfracture” enabled
by commercially manufactured bone picks used to
breach the subchondral bone [8]. Marrow-stimulating
technique procedures, in particular microfracture,
are now considered the first-line treatment for full-
thickness cartilage lesions and have demonstrated
good to excellent results in 60–80% of patients [148,
149].
Cartilage repair has evolved from marrow stimula-
tion techniques through to chondrocyte transplant
and now stem cells at rapid pace. An ideal transla-
tional pipeline would demonstrate how in vitro data
was used to inform a pre-clinical model, which would
later form a phase I/IIa first-in-man study and subse-
quently a phase III clinical trial. This would of course
be the safe and responsible method by which novel
therapies are brought to the market.
This systematic review is the first of its kind to explore
the full spectrum of evidence from in vitro studies,
through animal studies to human clinical trials, and yet,
we found little evidence of connectivity between in vitro,
animal and then human work. In fact, we did not find a
single group that had carried out and reported studies in
all three categories.
Indeed, even from groups, which showed a seemingly
hierarchical approach to translation, discrepancies
became apparent. For example, Saw et al. from Korea
used a pre-clinical goat model to repair cartilage defects
using HA plus bone marrow-derived cells [150] and then
moved into a first-in-man study, but in doing so, elected
to change from bone marrow aspirate to peripheral
blood and justified this change because it was easier to
harvest peripheral blood than marrow [151].
There are several sources of cells that have been
used in cartilage repair including bone marrow, per-
ipheral blood, synovium, adipose tissue and umbilicus
(Table 14) without any clear evidence of superiority
of one over the other.
One stage vs. two stages
As two stage procedures involving cell culture are
expensive and cumbersome, there is an increasing push
towards a single stage stem cell treatment. In this
situation there is some supportive pre-clinical data
[91, 95, 98, 152–154], but there does not appear to
be a pre-clinical study that directly compares bone
marrow concentrates against cultured MSCs.
Several groups have reported the use of bone marrow
concentrates in clinical practice [116, 117, 127, 128,
130–132], in which the buffy coat is used containing the
nucleated cells, of which a few will be stem cells.
Briefly, the patient has approximately 60 mL of bone
marrow harvested from the iliac crest which is then
spun down in a cell centrifuge (SmartPrep, Harvest
Technologies Corp., USA, or IOR-G1, Novagenit,
Mezzolombardo, TN, Italy) to provide 6 mL of concentrate
containing nucleated cells. A small amount of the nucle-
ated cells are then placed onto a hyaluronic acid mem-
brane (Hyalofast, Fidia Advanced Biopolymers, Italy) or
collagen membrane (IOR-G1, Novagenit, Mezzolombardo,
Table 12 Analysis technique used on repaired tissue





88 (79%) [49, 54–56, 58, 59, 61, 62, 64–69, 71–73, 75,
76, 78–89, 92, 95, 97, 98, 100, 101, 134, 150–152,
154, 160, 161, 273–280, 285–302, 304, 305, 307,
309, 310, 312, 314–324]
Collagen type II 84 (76%) [54, 56–59, 62, 65–73, 75–88, 90, 91, 93–96, 98,
100–102, 134, 150–154, 160, 161, 272–276,
278–282, 284–288, 292, 294–296, 300, 302–306,
308, 309, 311, 313–315, 317–319, 321, 323]
Cluster
Chondrocytes
34 (31%) [57, 60, 62, 63, 72, 74, 77, 78, 80, 81, 83, 84, 91, 97,
102, 151, 152, 160, 161, 273, 276, 280, 281, 283, 291,
292, 296, 297, 304, 312, 318, 319, 322, 324]
Glycosaminoglycan 40 (36%) [49, 62, 65, 67–71, 73–75, 81, 85, 87, 94, 96–101,
160, 272, 274, 279, 282, 286, 288, 290, 291, 296,
300, 301, 308, 309, 311, 312, 315, 319, 323]
Genes 22 (20%) [56, 60, 61, 63, 64, 66, 78, 80, 82, 90, 94, 96, 134,
275, 277, 283, 285, 294, 311, 316, 321, 323]
Proteoglycan 8 (7%) [56, 63, 84, 95, 98, 287, 294, 295]
Table 13 Number of publications for each study type and phase
Category No. of studies
(total 28)
References
Phases of clinical studies
Pilot/feasibility study incl. case report 15 (54%) [104–108, 118, 119,
122, 124–129, 133]
Phase 1 (safety assessment) 8 (26%) [109–112, 116, 123,
130, 131]
Phase 2 (efficacy assessment) 8 (26%) [103, 113–115, 117,
120, 121, 132]
Phase 3 (large scale efficacy assessment
through a multi-centre RCT)
0 (0%) –
Phase 4 (post-market surveillance) 0 (0%) –
Goldberg et al. Journal of Orthopaedic Surgery and Research  (2017) 12:39 Page 9 of 30





Bone marrow 22 (71%) [103–105, 109, 111–113,
115–118, 120, 122–128,
130–132]
Adipose 5 (16%) [106–108, 110, 114]
Peripheral blood 2 (6%) [119, 121]
Synovium 2 (6%) [129, 133]
Cell delivery
Arthroscopic implantation
Hyaluronic acid membrane 2 (6%) [117, 130]
Hyaluronic acid with fibrin
glue or platelet gel
2 (6%) [116, 128]
Polyglycolic acid/hyaluronan 2 (6%) [127, 131]
Collagen with platelet gel 1 (3%) [116]
Fibrin glue 1 (3%) [108]
HYAFF 11 scaffold 1 (3%) [132]
Acetate Ringer solution 1 (3%) [133]
Unspecified 1 (3%) [107]
Intra-articular injection
PBS only 2 (6%) [104, 110]
PBS with HA 2 (6%) [119, 121]
Autologous serum 2 (6%) [115, 123]
Ringer lactate solution 3 (10%) [103, 111, 112]
PBS with serum albumin 1 (3%) [105]
HA and PRP 1 (3%) [106]
PRP 1 (3%) [114]
Commercial serum 1 (3%) [109]
Transplantation by open surgery
Collagen 6 (21%) [103, 113, 118, 122, 124,
126, 129]
Ascorbic acid-mediated sheet 2 (7%) [120, 123]
Fibrin glue 1 (4%) [125]
Cell dose
Less than 10 million 8 (26%) [105, 107, 108, 114, 120,
122, 124, 129]
10–20 million 5 (16%) [113, 118, 119, 123, 125]
Over 20 million 7 (23%) [103, 104, 109–112, 133]
Unspecified 11 (35%) [106, 115–117, 121,
126–128, 130–132]
Follow-up
Up to 6 months 4 (13%) [104–106, 110]
Up to 12 months 6 (19%) [103, 109, 111, 124, 125, 127]
Up to 2 years 11 (35%) [107, 113–116, 120, 121,
128–131]
Up to 3 years 7 (23%) [108, 112, 117, 119, 122,
126, 132]
Over 3 years 2 (6%) [118, 133]
Table 14 Summary of the published clinical studies (Continued)
Assessments




17 (54%) [107, 108, 113, 116–122,
124–126, 130–133]
IKDC 10 (32%) [107, 108, 115, 121, 122,
126, 128, 130–132]
VAS pain 12 (39%) [103–106, 109–112, 114,
129, 131, 132]
Tegner activity scale 8 (26%) [107, 108, 114, 115, 129,
131–133]
Lysholm 6 (19%) [114, 115, 125, 128, 131, 133]
KOOS 5 (16%) [126, 128–130, 132]
Function (no scoring systems
or unspecified)
4 (13%) [104–106, 109]
ICRS cartilage injury evaluation package 3 (10%) [120, 123, 125]
Clinical symptoms/outcomes
(no scoring system or unspecified)
3 (10%) [105, 109, 124]
(Revised) Hospital for special
surgery knee-rating scale
2 (6%) [113, 125]
Functional Rating Index 2 (6%) [104, 106]
WOMAC 5 (16%) [103, 109–112]
AOFAS score 2 (6%) [112, 116, 117]
Knee Society Score 1 (3%) [110]





11 (35%) [113, 115, 118, 119, 121–123,
125, 127, 128, 131]
Debridement, synovectomy, excision
of degenerative tears (no subchondral
bone marrow stimulation)
8 (26%) [107, 108, 114, 116, 117,
124, 130, 133]
ACL reconstruction, meniscus




8 (26%) [115, 123, 126, 129–133]
None 6 (19%) [103, 105, 106, 110–112]




6 (19%) [104, 116, 117, 122, 125, 130]
Menisectomy 6 (19%) [103, 111, 124, 129, 131, 133]
ACL reconstruction 4 (13%) [103, 111, 131, 133]
Multiple (microfracture, debridement) 1 (3%) [119]
ACI 2 (6%) [116, 117]
None 6 (19%) [106–108, 110, 114, 118]
Not specified 9 (29%) [105, 109, 112, 115, 120,
121, 126, 128, 132]
PBS phosphate-buffered saline, HA hyaluronic acid, PRP plate-rich-plasma, RCT
randomised controlled study, KOOS Knee and Osteoarthritis Outcome Score,
IKDC score International Knee Documentation Committee Score, WOMAC the
Western Ontario and McMaster Universities Arthritis Index, AOFAS the American
Orthopaedic Foot & Ankle Society
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TN, Italy) as a scaffold, which is then arthroscopically
placed into the cartilage defect which had been pre-
prepared using a burr or drill. The construct is then held
with a platelet gel obtained from a harvest of 120 mL of
patient’s venous blood taken the day before surgery
(Vivostat system, (Vivolution, Denmark)) [118]. The results
of the first 30 patients have been reported as showing
improvements in MRI and arthroscopic appearance as well
as clinical scores at 3 years follow-up [118].
This new technique is of course an evolution of the
autologous matrix-enhanced chondrogenesis (AMIC)
which used the stem cells from the adjacent marrow
(and not pre-harvested bone marrow concentrates)
within either collagen patches [155–157] or polyglycolic
acid–hyaluronan-based scaffolds [158, 159].
There has also been a further step taken to avoid bone
marrow harvest in which peripheral blood has been used
in knee chondral lesions. In an RCT, arthroscopic sub-
chondral drilling was followed by postoperative intra-
articular injections of hyaluronic acid (HA) with and
without peripheral blood stem cells (PBSC). Fifty pa-
tients were studied and randomised 1 week after surgery
to receive either 8 injections of HA or 8 injections of
HA plus PBSC. Those that underwent PBSC received
stimulation with filgrastim, which contains recombinant
human granulocyte colony-stimulating factor prior to
harvest [106, 151]. At 18 month follow-up, they reported
no adverse effects and improved MRI findings in the
PBSC group compared to HA alone, took biopsies of 16
of the 25 patients in each group and claimed better tis-
sue morphology in the PBSC group, as graded by the
International Cartilage Repair Society Visual Assessment
Scale II. Interestingly, however, the same group’s pre-
clinical used bone marrow aspirates and not peripheral
blood [150].
Autologous vs. allogenic
There is an increasing interest in allogenic cells to avoid
donor site morbidity and to reduce cost. The pre-clinical
data with regards to allogenic cells is conflicting. One
group showed promising results of allogenic MSCs in a
rabbit model when compared to autologous cells,
although numbers were small [160, 161]. Another group
compared autologous chondroprogenitor cells and allo-
genic chondroprogenitor cells against controls in an
equine model and reported inferior repair in the allo-
genic cell group [23]. Despite conflicting pre-clinical
data, human studies using allogenic cells began in Korea
in 2009. A phase I/IIa study to assess safety and efficacy
of a combination of human umbilical cord blood-
derived mesenchymal stem cells and sodium hyaluronate
(CARTISTEM® (MEDIPOST Co., Ltd., Korea)) was per-
formed in knee chondral defects (NCT01041001). A par-
allel phase 3, open-label, multi-centre RCT comparing
CARTISTEM® and microfracture in knee chondral defects
was carried out in Korea and the USA (NCT01733186).
Results are still pending.
Another area of huge controversy is the actual dose of
cells that should be used. In vitro between 50,000 cells/
mL and 100 billion cells/ml have been studied. In pre-
clinical animal studies, this ranged from 1000 to 1 billion
cells/mL, and in human studies, the reported range has
been 1.2 million cells/mL–24 million cells/mL.
It remains unclear what the most appropriate cell dose
should be, with some groups reporting that a higher cell
number leads to a better repair [52, 71, 87, 95, 162–
164], but Zhao et al. [99] highlighted the limitation to
cell saturation and survival, and thus, there may be a top
limit to cell number that can be used to aid repair.
A multitude of methods for cell delivery have also
been adopted, from direct joint injection or embedded
in a plethora of scaffolds, such as type I collagen gels of
porcine or bovine origin, ascorbic acid sheets or fibrin
glues (Table 14).
In vitro and in pre-clinical studies, a plethora of
growth factors have been studied including TGF-β1 and
TGF-β2 and BMP-7 but none of these have been
included in human clinical trials (Table 5).
It is clear that the relationship between cell passage,
cell dose, the use of scaffolds and growth factors and the
efficacy of MSC treatment is still to be established.
Future
There is no question that the field of cartilage repair
accelerates at rapid pace, and it is clear that the single
stage procedures are likely to win over two stage proce-
dures to save costs and reduce the burden on both pro-
vider and the patient. The reduction of donor site
morbidity is a further driver helping direct progress.
The concept of cell banks of allogenic cells clearly
meets all of the above criteria, but the lack of good sup-
porting pre-clinical and long-term safety and efficacy
data does little to pacify potential pitfalls of this
direction. The fact that the phase 3 RCT of allogenic
umbilical stem cells was allowed to be registered
(NCT01041001) before the same group registered their
phase I/IIa safety study (NCT01733186) intimates that
sometimes clinical pace exceeds that of the regulators to
lay down new ground.
Tools are likely to be introduced to the operating
theatre that might improve the efficacy of treatment,
such as fluorescence-activated cell sorting (FACS)
machines which can isolate MSCs from the buffy coat of
bone marrow aspirate by their cell surface markers. At
present, this technology is expensive and complicated
and ways to reduce cost and make the process simple
are required before they could enter the operating
theatre.
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Induced pluripotent stem cells (iPSCs) are adult
somatic cells that have been genetically reprogrammed
to an embryonic stem cell-like state by being forced to
express genes and factors important for maintaining the
defining properties of embryonic stem cells [165].
These cells show unlimited self-renewal, and some in
vitro studies have shown chondrogenic differentiation by
iPSCs from human chondrocytes biopsied from osteo-
arthritic knees [166] and cartilage formation from hu-
man neural stem cells [167]. However, this work is at a
very early stage, and aside from the ethical consider-
ations, much research into control of cell phenotype and
cell fate to alleviate concerns for cancer risk are required
before this technology is ready to move into the pre-
clinical and clinical realms.
In conclusion, this review is a comprehensive assess-
ment of the evidence base to date behind the translation
of basic science to the clinical practice of cartilage
repair. We have revealed a lack of connectivity between
the in vitro, pre-clinical and human data and a patch-
work quilt of synergistic evidence. It appears that the
drivers for progress in this space are largely driven by
patient demand, surgeon inquisition, and a regulatory
framework that is learning at the same pace as new
developments take place. We strongly recommend fund-
ing body commission studies that have a clear transla-
tional purpose in order to drive the science towards
patient benefit.
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